SEC Form 4 · accession 0001140361-16-085619
Loxo Oncology, Inc. · LOXO
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Steve Harr
Director
Period of report
Nov 7, 2016
Accepted (ET)
Nov 9, 2016 · 4:45 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001581720
Table I — non-derivative securities
No Table I lines on this filing.
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Director Stock Option (right to buy)F1 | $19.66 | Nov 7, 2016 | A | 15,625 | A | — | Nov 6, 2026 | Common Stock | 15,625 | 15,625 | D |
Explanation of responses
- F1The stock option vests and becomes exercisable as to 1/3 of the shares subject to the option on the one-year anniversary of the grant date, and thereafter vests as to an additional 1/3 of the shares annually.